Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

62.06
+1.292.12%
Post-market: 63.271.21+1.95%17:26 EDT
Volume:691.13K
Turnover:43.14M
Market Cap:2.38B
PE:-9.46
High:63.50
Open:60.67
Low:60.03
Close:60.77
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:0.87
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:3.70
PE(LYR):-10.32

Loading ...

Disc Medicine’s APOLLO Trial Completion: A Pivotal Moment for IRON Investors

TIPRANKS
·
5 hours ago

Analysts Are Bullish on These Healthcare Stocks: Ligand Pharma (LGND), Disc Medicine (IRON)

TIPRANKS
·
Sep 22

U.S. Research Roundup-Domino's, McDonald's, Starbucks

Reuters
·
Sep 16

Disc Medicine Price Target Maintained with a $100.00/Share by Wedbush

Dow Jones
·
Sep 10

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

TIPRANKS
·
Sep 10

Disc Medicine Highlights Bitopertin Phase 3 EPP Program in Corporate Presentation

Reuters
·
Sep 10

Disc Medicine Says Restore-PV Phase 2 Trial Shows DISC-3405 Cuts Phlebotomy Needs in Polycythemia Vera Patients

Reuters
·
Sep 10

Disc Medicine Presents Initial Results from Restore-Pv Phase 2 Trial in Patients with Polycythemia Vera (Pv) at the 14TH Society of Hematologic Oncology (Soho) Annual Meeting

THOMSON REUTERS
·
Sep 10

Disc Medicine Director Kevin Bitterman Reports Disposal of $135,824.04 in Common Shares

Reuters
·
Sep 10

Disc Medicine Director Kevin Bitterman Disposes of USD 4.36 Million in Common Shares

Reuters
·
Sep 04

Disc Medicine is Maintained at Outperform by Wedbush

Dow Jones
·
Sep 02

Disc Medicine Management Joins Fireside Chats at Upcoming Investor Conferences

Reuters
·
Sep 02

Wedbush Raises Price Target on Disc Medicine to $100 From $88, Keeps Outperform Rating

MT Newswires Live
·
Sep 02

Disc Medicine, Inc. : Wedbush Raises Target Price to $100 from $88

THOMSON REUTERS
·
Sep 02

Disc Medicine to Present Initial Phase 2 Restore-PV Data for DISC-3405 in Polycythemia Vera at SOHO 2026

Reuters
·
Sep 01

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

GlobeNewswire
·
Sep 01

Disc Medicine COO Jonathan Yen-Wen Yu Disposes of 9,096 Common Shares Worth $755,192.83

Reuters
·
Aug 27

Disc Medicine CEO John D. Quisel Disposes of USD 2.63 Million in Common Shares

Reuters
·
Aug 19

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Morgan Stanley Adjusts Price Target on Disc Medicine to $90 From $85, Keeps Overweight Rating

MT Newswires Live
·
Aug 17